Table 3.

Estimated^a differences in change in hematologic, chemistry, and respiratory parameters and inflammatory markers from day 1 to day 15.

Parameter	With Eculizumab		Without Eculizumab		β Difference	P-Valuec
	n	βb	n	βb
Platelets, 109/L	35	10.4	45	4.8	−5.6	<0.001
Prothrombin time,% ratio patient/control	35	−0.4	45	−0.9	−0.5	0.004
Fibrinogen, g/L	35	−0.1	45	−0.1	0.01	0.7
D-dimers, ng/mL	35	−88.4	41	320.8	409.2	0.1
Creatinine, μmol/L	35	2.5	45	2.6	0.05	0.9
Blood urea nitrogen, mmol/L	35	0.09	45	0.4	0.3	<0.001
Lymphocytes, 109/L	35	0.06	44	0.05	−0.01	0.8
Procalcitonin, μg/L	35	−0.009	44	0.2	0.2	0.3
CRP, mg/L	35	−3.3	45	−3.5	−0.2	0.9
Total bilirubin, μmol/L	35	0.4	45	1.9	1.5	<0.001
Conjugated bilirubin, μmol/L	35	0.3	44	1.5	1.2	<0.001
Troponin T, ng/L	35	−1.9	45	−1.6	0.3	0.9
PaO2/FiO2, mmHg	35	2.8	45	0.1	−2.7	0.006
Lactate, mmol/L	35	−0.03	19	0.1	0.1	0.003
TNF-α	29	–3.1	19	–1.2	1.9	0.06
IL-1β	28	–0.38	17	–0.18	0.20	0.07
IL-6	29	–53.6	19	–9.8	43.8	0.04
IL-8	29	–6.3	19	2.5	8.8	0.20
IL-1RA	29	–87.1	19	–21.7	65.4	0.60
IL-4	29	–0.05	19	–0.03	0.02	0.30
IL-10	29	7.4	19	–0.1	–7.5	0.60
IL-17	29	–0.3	19	0.1	0.4	0.01
IFN-α2	29	–0.2	19	–0.07	0.13	0.03
IFN-γ	29	–1.4	19	0.3	1.7	0.08

CRP=C-reactive protein; IFN=interferon; IL=interleukin; IL-1RA=IL-1 receptor antagonist; PaO2/FiO2=ratio of partial pressure of oxygen to fractional inspired oxygen; TNF=tumor necrosis factor. Laboratory data were collected up to day 15 (time point for primary outcome) or up to death or ICU discharge.

^aChanges in laboratory values over time were assessed using linear mixed models for longitudinal data with a time by group effect.

^bSlope of change in parameter over time.

^cCalculated with linear mixed model for longitudinal data with time-by-group effect.